Codiak’s exoASO-C/EBPβ was a novel therapeutic that selectively targets the transcription factor C/EBPβ in immunosuppressive myeloid-derived suppressor cells (MDSCs), leading to immune modulation and potent systemic anti-tumor activity across multiple MDSC-rich, checkpoint-resistant tumor models. Here, CEBPB is linked to neoplasm.